Antonio Regalado

A View from Antonio Regalado

Crowding into Biotech’s Densest Supercluster

Boston may overtake Silicon Valley at the top of the biotech heap.

  • June 27, 2013

Is Boston going to pass Silicon Valley as the ground zero for the biotechnology industry? Some people think it might.

Serial entrepreneur: What successful technology
regions eat for breakfast.

In July, MIT Technology Review will begin publishing a month-long report about “innovation clusters.” Sounds like a fortified breakfast cereal for entrepreneurs, right?

Instead, what I’m talking are those intense geographic concentrations of related companies, researchers, and labs that always seem to dominate new technology. The most famous cluster in the world is Silicon Valley. And it has ruled for years in both computer technology and biotechnology.

But recently, there are signs that Boston and adjacent Cambridge – specifically the area around Kendall Square, near MIT – might just break away and take the lead.

Just a few blocks on a side, Kendall is tightly packed with big academic laboratories like the Broad Institute. I’m guessing it’s probably the densest concentration of deep thinkers in genetics, neuroscience and genome research anywhere in the world.

Boston has always had some large, home-grown biotechnology firms, like Genzyme. But Jean-Francois Formela, an investor at Atlas Venture, says the region began to accelerate in 2002 when Swiss drug outfit Novartis decided to move its global R&D operations to Cambridge. Since then, more and more drug companies have arrived. Just yesterday, I got a press release from Johnson & Johnson saying that it would be unveiling a 9,000 square foot “innovation center” in the area.

The space will have an open floor plan, the kind of place people can come and go and just bat around ideas (“A very different kind of space than J&J usually has,” a press representative told me.) And J&J left no doubt about what they are looking for: the word “innovation” appeared 20 times in the email they sent us. 

When I think of drug companies, I usually picture a corporate campus somewhere in New Jersey floating in a square mile of bright-green lawn. But that model isn’t working any more. Drug companies are having a hard time coming up with enough new medicines on their own.

Part of what’s happening is a shift from chemistry to biology as a way to find drugs. The exciting new ideas are coming out of research into the human genome—often, the drugs being developed are actually biological molecules. That’s exactly the kind research taking at places like MIT and Harvard’s Longwood Medical campus, across the Charles River.

Another reason to be near the heart of a cluster is to be close to where the deals get made. Venture outfits like Formela’s Atlas Venture and Third Rock Ventures are the ones that pull together the new science and package it into startup companies that companies like J&J can buy into.

Formela says the exceptionally tight concentration of biotechnology talent in Boston is what lets him do that. “I can build a team with incredible speed,” he says. Unlike in Silicon Valley, which is spread out, in Boston people don’t have to re-locate to take a new job. “A lot of times people don’t even have to change buildings, they just move floors,” says Formela.

Companies are paying dearly for a seat near the action. Boston’s biotech cluster overlaps with a fast-growing concentration of technology firms—Google, Nokia, Amazon, and PayPal have all expanded into the area—and rents have spiked to around $70 per square foot, twice what they were six or seven years ago.

“You have big pharma coming in on top of a resurgence of tech companies, so it’s a real cocktail for high rents,” says Kevin Malloy, who leases office and lab space at real-estate company Avison Young. “They are all looking for those unplanned meetings, those situations where you can run into someone and be collaborative.”

The big question is whether Boston will take the biotech crown from Silicon Valley. According to Formela, Boston now leads in many metrics, including government funding for medical research. One area where Silicon Valley is still ahead is total venture capital dollars invested. According to Pricewaterhouse Coopers, Silicon Valley biotechnology companies raised $1 billion in 2012, versus $860 million for Massachusetts companies. The two regions are about neck in neck when it comes to early, seed-stage investments.

Of course, California has been fighting back, putting out reports reminding people it’s still the largest concentration of biomedical companies in the world. But the Boston-Cambridge cluster is going to get bigger, and denser too. In April, the Cambridge City Council approved an MIT petition to develop 26 acres around its campus and put up buildings twice as high as currently.

“The gravity field is going to be overwhelming,” Formela predicts. “It will be the biotech center of the world.”

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.
Subscribe today

Uh oh–you've read all five of your free articles for this month.

Insider Premium

$179.95/yr US PRICE

More from Business Impact

How technology advances are changing the economy and providing new opportunities in many industries.

Want more award-winning journalism? Subscribe and become an Insider.

  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look. Exclusive early access to stories.

    Insider Conversations. Join in and ask questions as our editors talk to innovators from around the world.

  • Insider Plus {! insider.prices.plus !}* Best Value

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning magazine and daily delivery of The Download, our newsletter of what’s important in technology and innovation.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

You've read of free articles this month.